The Keri Lab has a record of publishing research in high-impact peer-reviewed journals. Below are the most recent publications from our lab. The National Center for Biotechnology Information contains an up-to-date list of all publications


Targeting bromodomain and extraterminal proteins in breast cancer. Sahni JM, Keri RA. Pharmacol Res. 2018 Mar;129:156-176. doi: 10.1016/j.phrs.2017.11.015. Epub 2017 Nov 16. Review.

BETi induction of mitotic catastrophe: towing the LIN9. Gayle SS, Sahni JM, Keri RA. Oncoscience. 2017 Oct 23;4(9-10):128-130. doi: 10.18632/oncoscience.372. eCollection 2017 Sep.

Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors. Sahni JM, Gayle SS, Webb BM, Weber-Bonk KL, Seachrist DD, Singh S, Sizemore ST, Restrepo NA, Bebek G, Scacheri PC, Varadan V, Summers MK, Keri RA. Cancer Res. 2017 Oct 1;77(19):5395-5408. doi: 10.1158/0008-5472.CAN-17-1571. Epub 2017 Aug 14.

Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer. Seachrist DD, Sizemore ST, Johnson E, Abdul-Karim FW, Weber Bonk KL, Keri RA. Breast Cancer Res. 2017 Jun 5;19(1):66. doi: 10.1186/s13058-017-0857-y.

Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases. Sahni JM, Gayle SS, Bonk KL, Vite LC, Yori JL, Webb B, Ramos EK, Seachrist DD, Landis MD, Chang JC, Bradner JE, Keri RA. J Biol Chem. 2016 Nov 4;291(45):23756-23768. Epub 2016 Sep 20.